Combination of Ginsenoside H and Vinorelbine for Lung Cancer Treatment
Author Information
Author(s): Li Xinxin, Chen Fengfei, Yang Rui, Song Zhaohui, Ma Xiaohui, Sun Li, Yuan Shengtao
Primary Institution: Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University
Hypothesis
Can a combination of Ginsenoside H and Vinorelbine effectively treat recurrence of Non-Small Cell Lung Cancer (NSCLC)?
Conclusion
The combination of Ginsenoside H and Vinorelbine significantly reduces tumor recurrence and improves quality of life in a mouse model of lung cancer.
Supporting Evidence
- The inhibition rate of the combined treatment was 74.81%, significantly higher than using either drug alone.
- 12 metabolites showed significant differences in abundance between treatment groups and the model group.
- The combination therapy improved the quality of life indicators in the mouse model.
Takeaway
This study shows that using two medicines together can help fight lung cancer better than using just one.
Methodology
A mouse model of lung cancer was created, and the effects of Ginsenoside H and Vinorelbine were evaluated through tumor weight measurements and metabolomic analysis.
Limitations
The study was conducted on mice, and results may not directly translate to humans.
Participant Demographics
10-week-old adult male C57BL/6 mice
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website